
Menten AI
Menten AI is a YC Winter 2020 (W20) company. Based in San Francisco, CA, USA. Team of 2.
About Menten AI
Summary
Menten AI builds a physics-based generative AI platform, MAUD 1.0, for designing peptide macrocycle drugs from scratch. The platform combines generative AI, physics-based models, and quantum simulations to create drug candidates against complex targets, including protein-protein interfaces, replacing traditional high-throughput screening. Pharmaceutical and biotech companies use it to accelerate preclinical discovery of peptides with oral bioavailability, cell permeability, and nanomolar potency.
Go-to-market
Top-10 pharma companies are the primary customers, engaged through partnerships and pilot projects on specific drug discovery programs.
From the Y Combinator listing
Menten AI designs peptide and protein therapeutics using quantum…
Menten AI designs protein drugs and enzymes using quantum computing and machine learning. Their technology leapfrogs current computational methods making it possible to design previously intractable proteins. The team created the first protein design algorithm for current and near-term quantum computers and created the world’s first protein designed on a quantum computer. They are now working on 3 new proteins, including a peptide to prevent the spread of viruses like Covid-19. They have 2 paid pilot projects with multinational chemical companies and 4 LOI’s with pharma and biotech companies.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (2)
- Hans Melo
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works